MRI research, from the physics to the endpoint.
Signal Agency is a research MRI group in Boston. We design the imaging behind sponsored trials and investigator studies in neurodegenerative disease and oncology, and we evaluate imaging concepts for the investors deciding whether to back them.
For pharma and biotech sponsors and their CROs
Imaging, designed into the trial
Imaging is some of the most expensive data a trial collects, and the hardest to repair afterward. A scan acquired the wrong way at one site cannot be taken again a year later.
We do the work before the first scan, so the images from every site answer the same question. We work alongside your CRO and imaging core lab, on the part of the study that happens at the scanner.
Feasibility review
We check that the endpoint can be measured on the scanners your sites own, in a scan time patients will tolerate, before the budget is set.
Protocol design
An acquisition protocol built around the endpoint and matched across Siemens, GE, Philips, Canon, United Imaging and Fujifilm systems. Every parameter and tradeoff is written down for the imaging manual.
Site readiness
We build the protocol onsite with each site's technologists, run phantom and volunteer scans, and leave a protocol card the night shift can follow.
Quality monitoring
Image quality review while the study enrolls, so drift at one site is caught at scan ten instead of at database lock.
For research groups
Research areas
Where our physicists, technologists and study designers spend their time.
Neurodegenerative disease
Imaging for studies in Alzheimer's disease, Parkinson's disease and related disorders: volumetric, diffusion and susceptibility protocols held consistent across sites and visits.
Cancer studies
Imaging endpoints for oncology research: lesion measurement, diffusion and perfusion protocols, and reader studies designed around the trial's question.
Low field MRI
Protocol development below 1.0 T. We work out what holds at lower field, what to give up, and where it wins outright on cost, access and imaging near metal.
Nuclear magnetic resonance
Physics level work on relaxation, diffusion and chemical shift, for groups developing new contrasts and sequences.
For academic and clinical investigators, we take a study from pilot design through volunteer validation and reader review to the abstract and the manuscript.
How an engagement runs
One question, one protocol, one deliverable. Most run three to six months.
-
Scope
The question, the scanners and the endpoint, agreed in writing before anyone scans.
-
Build
The protocol built on the actual systems, with the site's technologists in the room.
-
Validate
Phantom, volunteer or patient scans, reader review, and the numbers behind the result.
-
Deliver
A protocol card any site can run, the pages for the imaging manual, and the abstract when there is one to write.
Each engagement is staffed from a bench of MR physicists, technologists and study designers, brought in per project.
For investors
A second read before the term sheet
For venture investors, we pressure test medical imaging concepts before a commitment: hardware, software and the services built around them.
We read a pitch the way we read a study protocol, against the physics, the scanners already installed, and the people who would have to use it.
What an evaluation answers
- Does the physics hold, or does the result depend on conditions a hospital cannot reproduce?
- Will it run on the installed base, across the vendors, field strengths and software versions sites own today?
- What does it take to connect, from DICOM and PACS to the hospital's IT review?
- What study would prove the claim, and how long would that study take?
You get a written evaluation and a conversation, scoped to the decision in front of you.
Now scoping studies and evaluations for 2027
Tell us the question, the scanners involved and when you need an answer.
Boston, Massachusetts. Onsite anywhere in the United States.
Signal Agency is part of M10 International.